252 related articles for article (PubMed ID: 23924389)
1. Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study.
Alkharfy KM; Al-Daghri NM; Sabico SB; Al-Othman A; Moharram O; Alokail MS; Al-Saleh Y; Kumar S; Chrousos GP
Cardiovasc Diabetol; 2013 Aug; 12():113. PubMed ID: 23924389
[TBL] [Abstract][Full Text] [Related]
2. A 6-month "self-monitoring" lifestyle modification with increased sunlight exposure modestly improves vitamin D status, lipid profile and glycemic status in overweight and obese Saudi adults with varying glycemic levels.
Al-Daghri NM; Alfawaz H; Aljohani NJ; Al-Saleh Y; Wani K; Alnaami AM; Alharbi M; Kumar S
Lipids Health Dis; 2014 May; 13():87. PubMed ID: 24884616
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study.
Al-Daghri NM; Alkharfy KM; Al-Othman A; El-Kholie E; Moharram O; Alokail MS; Al-Saleh Y; Sabico S; Kumar S; Chrousos GP
Cardiovasc Diabetol; 2012 Jul; 11():85. PubMed ID: 22809461
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Home PD; Jones NP; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Komajda M; Curtis P;
Diabet Med; 2007 Jun; 24(6):626-34. PubMed ID: 17517066
[TBL] [Abstract][Full Text] [Related]
5. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
[TBL] [Abstract][Full Text] [Related]
6. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
[TBL] [Abstract][Full Text] [Related]
9. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
Atamer Y; Atamer A; Can AS; Hekimoğlu A; Ilhan N; Yenice N; Koçyiğit Y
Braz J Med Biol Res; 2013 Jun; 46(6):528-32. PubMed ID: 23802228
[TBL] [Abstract][Full Text] [Related]
11. Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
Orbay E; Sargin M; Sargin H; Gözü H; Bayramiçli OU; Yayla A
Endocr J; 2004 Dec; 51(6):521-7. PubMed ID: 15644569
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Gupta M; Braga MB; Verma S
Can J Cardiol; 2008 Oct; 24(10):e65-9. PubMed ID: 18841263
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
14. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Chogtu B; Singh NP; Chawla S; Gupta U
Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Dargie H; Komajda M; Gubb J; Biswas N; Jones NP
Diabetologia; 2005 Sep; 48(9):1726-35. PubMed ID: 16025252
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D3 as adjuvant in the treatment of type 2 diabetes mellitus: modulation of genomic and biochemical instability.
Fagundes GE; Macan TP; Rohr P; Damiani AP; Da Rocha FR; Pereira M; Longaretti LM; Vilela TC; Ceretta LB; Mendes C; Silveira PCL; Teixeira JPF; de Andrade VM
Mutagenesis; 2019 May; 34(2):135-145. PubMed ID: 30726950
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Home PD; Pocock SJ; Beck-Nielsen H; Curtis PS; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
Lancet; 2009 Jun; 373(9681):2125-35. PubMed ID: 19501900
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D supplementation and serum levels of magnesium and selenium in type 2 diabetes mellitus patients: gender dimorphic changes.
Al-Daghri NM; Alkharfy KM; Khan N; Alfawaz HA; Al-Ajlan AS; Yakout SM; Alokail MS
Int J Vitam Nutr Res; 2014; 84(1-2):27-34. PubMed ID: 25835233
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
